ACS Cancer Research Program

More in this category

• ACS Clinical Research Program sessions at Clinical Congress 2019: A recap
• Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial
• ALCHEMIST trial has potential to improve outcomes after lung cancer resection
• Could axillary reverse mapping be useful in reducing surgical comorbidities?
• Evolution in the management of desmoid tumors: Challenging the role of upfront surgical resection
• Putting the needle before the knife: Minimally invasive approaches to diagnostic lymph node biopsy in melanoma
• Gastric cancer: Recent updates in surgical and multimodality therapy
• Organ preservation in rectal adenocarcinoma: The OPRA Trial
• Opportunities at Clinical Congress 2019 to increase surgeon participation in clinical research
• Defining the optimal treatment of locally advanced gastric cancer
• Preoperative smoking intervention techniques improve outcomes for lung cancer patients
• Atezolizumab in the adjuvant treatment of stage III colon cancer: Can PD-L1 inhibition improve survival?
• Cytoreduction with or without HIPEC: Where do we go from here?
• Robotic surgery for hepatic neoplasms: Where does it fit in the minimally invasive surgery landscape?
• Surveillance testing for colorectal cancer: New evidence supports a change in guidelines
• Colorectal cancer in adults younger than 50 years old
• The evolving clinical management of sentinel node-positive melanoma: The impact of MSLT-II on clinical practice
• Liquid biopsies in cancer clinical trials
• Geriatric assessment and frailty in older cancer patients
• Immunotherapy in solid tumors